Affiliation:
1. Boston Children's Hospital, Harvard Medical School
2. Washington State University
3. University of Verona
4. Baylor Scott & White Research Institute
5. University Children’s Hospital Heidelberg
6. Institut de Recerca, Hospital Sant Joan de Déu
Abstract
Abstract
Objective
To investigate the genotype-to-protein-to-phenotype correlations of succinic semialdehyde dehydrogenase deficiency (SSADHD), an inherited metabolic disorder of γ-aminobutyric acid catabolism.
Methods
Bioinformatics and in silico mutagenesis analyses of ALDH5A1 variants were performed to evaluate their impact on protein stability, active site and co-factor binding domains, splicing, and homotetramer formation. Protein abnormalities were then correlated with a validated disease-specific clinical severity score and neurological, neuropsychological, biochemical, neuroimaging, and neurophysiological metrics.
Results
A total of 58 individuals (1:1 male/female ratio) were affected by 32 ALDH5A1 pathogenic variants, eight of which were novel. Compared to individuals with single homotetrameric or multiple homo and heterotetrameric proteins, those predicted not to synthesize any functional enzyme protein had significantly lower expression of ALDH5A1 (p = 0.001), worse overall clinical outcomes (p = 0.008) and specifically more severe cognitive deficits (p = 0.01), epilepsy (p = 0.04) and psychiatric morbidity (p = 0.04). Compared to individuals with predictions of having no protein or a protein impaired in catalytic functions, subjects whose proteins were predicted to be impaired in stability, folding, or oligomerization had a better overall clinical outcome (p = 0.02) and adaptive skills (p = 0.04).
Conclusions
The quantity and type of enzyme proteins (no protein, single homotetramers, or multiple homo and heterotetramers), as well as their structural and functional impairments (catalytic or stability, folding, or oligomerization), contribute to phenotype severity in SSADHD. These findings are valuable for assessment of disease prognosis and management, including patient selection for gene replacement therapy. Furthermore, they provide a roadmap to determine genotype-to-protein-to-phenotype relationships in other autosomal recessive disorders.
Publisher
Research Square Platform LLC
Reference44 articles.
1. Assessing Prevalence and Carrier Frequency of Succinic Semialdehyde Dehydrogenase Deficiency;Martin K;J Child Neurol,2021
2. Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification;Pearl PL;Dev Med Child Neurol,2015
3. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency;Pearl PL;Neurology. 2003 May
4. Enzyme Replacement Therapy for Succinic Semialdehyde Dehydrogenase Deficiency: Relevance in γ-Aminobutyric Acid Plasticity;Lee HHC;J Child Neurol,2021
5. Redox-switch modulation of human SSADH by dynamic catalytic loop;Kim YG;EMBO J. 2009 Apr
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献